Journal of Histochemistry and Cytochemistry, Vol. 48, 755-760, June 2000, Copyright © 2000, The Histochemical Society, Inc.


ARTICLE

Thymidylate Synthase Expression in Patients with Colorectal Carcinoma Using a Polyclonal Thymidylate Synthase Antibody in Comparison to the TS 106 Monoclonal Antibody

Baukelien Van Triesta, Barbara M. Loftusc, Herbert M. Pinedoa, Harold H.J. Backusa, Pascale Schoenmakersa, Frank Tellemana, Thea Tademab, G. Wynne Ahernef, Cornelius J. Van Groeningena, Frans A.N. Zoetmulderd, Babs G. Taale, Patrick G. Johnstong, and Godefridus J. Petersa
a Departments of Medical Oncology, University Hospital VU, Amsterdam, The Netherlands
b Pathology, University Hospital VU, Amsterdam, The Netherlands
c Departments of Pathology, Netherlands Cancer Institute/Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
d Surgery, Netherlands Cancer Institute/Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
e Gastroenterology, Netherlands Cancer Institute/Antoni Van Leeuwenhoekhuis, Amsterdam, The Netherlands
f Department of Drug Development, Cancer Research Campaign, Institute for Cancer Research, Sutton, United Kingdom
g Department Oncology, Queen's University of Belfast, Belfast, United Kingdom

Correspondence to: Godefridus J. Peters, Dept. of Medical Oncology, University Hospital VU, PO 7057, 1007 MB Amsterdam, The Netherlands. E-mail: gj.peters@azvu.nl


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Colorectal cancer is one of the most common human cancers, for which 5-fluorouracil (5FU) is usually part of the treatment. Thymidylate synthase (TS), the target enzyme for 5FU, can be predictive for the outcome of 5FU-based therapy. TS levels in tumor samples can be determined with radiochemical enzyme assays, RT-PCR, and immunohistochemical staining. We validated TS immunohistochemistry with a polyclonal rabbit anti-human TS antibody using the avidin–biotin method. This antibody can be used on paraffin-embedded, formalin-fixed material using an antigen retrieval method with citrate buffer and microwave treatment. The antibody shows a granular cytosolic staining pattern. The reproducibility in cross-sections from colorectal tumors from 50 patients was 90% and the interobserver variability was acceptable with a kappa of 0.45. On Western blotting it detects purified TS at 36 kD, while in 5FU-treated cells the ternary complex between FdUMP, TS, and 5,10-methylene-tetrahydrofolate is clearly visible at 38 kD, with no other interfering bands. In a separate set of tumors, immunostaining was compared with enzyme levels; Western blots correlated with enzyme levels. Because both this polyclonal antibody and the monoclonal antibody TS-106 are being used for large-scale studies, we also determined whether they could be used interchangeably. No differences were observed. This polyclonal antibody is specific and gives reproducible results. A study on a larger scale is ongoing to determine the role of TS as a predictive parameter in patients with colorectal cancer treated either with postoperative adjuvant 5FU/levamisole or with surgery only.

Key Words: thymidylate synthase, immunohistochemistry, polyclonal antibody, colorectal cancer


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Thymidylate synthase (TS; EC 2.1.1.45) is the limiting irreversible step in de novo DNA synthesis because it catalyzes the methylation of dUMP to dTMP. It is the target for the widely used anticancer agents 5-fluorouracil (5FU) and fluorodeoxyuridine (Pinedo and Peters 1988 ) and for several novel antifolate-based TS inhibitors such as ZD1694 (Tomudex, Raltitrexed), GW1843U89, LY231514, and AG337 (Thymitaq) (reviewed by Jackman and Calvert 1995 ; Peters and Ackland 1996 ; Rustum et al. 1997 ). 5FU is active against solid tumors such as gastrointestinal cancer, breast cancer and head and neck cancer. The antifolates have also shown activity against these tumors, and LY231514 also against non-small-cell lung cancer.

Clinical drug resistance at the TS level is of relevance for response to 5FU; increased TS mRNA, insufficient TS inhibition by 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), increase of TS levels after treatment are all mechanisms of 5FU resistance related to TS (reviewed by Peters and Jansen 1996 ). Several studies suggest a prognostic significance for TS in relation to 5FU-based therapy in advanced disease. In patients with gastric and colorectal cancer treated with 5FU-based chemotherapy, response to therapy and survival were statistically significantly related to TS mRNA (Leichman et al. 1995 ; Lenz et al. 1996 ).

In a previous study we measured TS levels enzymatically in patients with advanced colorectal cancer and found a significant relationship between the response to 5FU therapy and the TS levels (Peters et al. 1994 ). In rectal cancer and in advanced head and neck cancer patients treated with adjuvant and neoadjuvant 5FU-based chemotherapy, respectively, TS was an independent prognostic marker for disease-free and overall survival when measured by immunohistochemistry (Johnston et al. 1994 , Johnston et al. 1997 ).

TS levels in patient samples can be measured by various methods. With enzymatic assays (Peters et al. 1987 , Peters et al. 1991 ), the number of FdUMP binding sites and the TS catalytic activity (the conversion from dUMP to dTMP) can be quantified with radioactively labeled substrate. A drawback is the requirement of about 100 mg freshly frozen tissue. With RT-PCR, the TS mRNA level can be measured (Lenz et al. 1995 ). This assay can be performed on small biopsy samples but needs technical expertise to measure the mRNA level reliably. A disadvantage of both assays is that the tumor morphology is lost. Because tumor samples often also contain normal cells, TS values are dependent on the purity of the samples. With immunohistochemistry, tumor and normal cells can be discriminated. Another advantage of immunohistochemistry is that this assay can be performed on a larger scale (e.g., at more centers), which is of interest for study, e.g., of patients treated with adjuvant chemotherapeutic regimens. TS expression using immunohistochemistry with a monoclonal antibody against human TS, TS-106, has been extensively characterized previously (Johnston et al. 1991 , Johnston et al. 1992 ; Drake et al. 1993 ; Edler et al. 1997 ). The use of a TS polyclonal antibody has been reported on cytospins of tumor cell lines from different origin (Van der Wilt et al. 1993 ), in ELISA methods (Aherne et al. 1992 ; Van der Wilt et al. 1997 ) and in paraffin embedded material (Findlay et al. 1997 ).

In this article we describe the methodology and validation of the use of a polyclonal TS antibody for quantitation of TS levels in paraffin-embedded material from 50 representative patients with colorectal cancer. A secondary aim of the study was a comparison of the polyclonal antibody with the monoclonal TS-106 to establish their interchangeability. We also tested the intensity of the (immuno)staining compared with TS enzyme levels. Samples were obtained from patients who were entered in the Netherlands Adjuvant Colorectal Cancer Project (NACCP) trial in which postoperative 5FU/levamisole is compared to surgical treatment only in patients with colorectal cancer.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Tissues
Formalin-fixed, paraffin-embedded material from the primary tumors from 50 randomly selected patients with colorectal cancer were used. These patients were entered in the NACCP trial. In this trial, patients with colon and rectal cancer were randomized between surgical treatment only or surgery followed by 5FU combined with levamisole (Reynolds 1995 ). Samples were obtained at surgery from the group of patients evaluated in this study; 66% had colon cancer and the remainder rectal cancer. Both Dukes Stage B and C were included in this group, with an equal ratio for the colon tumors, whereas the majority of rectal tumors were Dukes B. In this patient group the male:female ratio was equal and the median age was 64 years. The majority of the tumors were moderately differentiated. From a separate group of untreated patients, we were also able to obtain biopsy specimens that were immediately frozen in liquid nitrogen for use in measurement of TS levels by an enzyme assay.

Immunohistochemical Staining
Tissue sections were cut at 4 µm, and mounted on poly-L-lysine-coated slides, and dried. The sections were deparaffinized and rehydrated by incubation twice for 3 min in 100% xylene, followed by incubation in decreasing ethanol concentrations. Antigen retrieval was necessary (Freemantle et al. 1991 ; Taylor et al. 1994 ; Brown and Chirala 1995 ) for the immunostaining on paraffin-embedded, formalin-fixed material with the TS polyclonal antibody (kindly provided by Dr. G.W. Aherne; Sutton, UK) or with the TS monoclonal antibody TS-106. Therefore, the sections were heated in the microwave twice for 5 min in 10 mM sodium-citrate buffer (pH 6.0) at 750 W. For the second heating step, fresh citrate buffer was used. The sections were then allowed to cool down in the buffer for at least 20 min. The sections were washed with PBS and blocked with normal goat serum (1:50) for 20 min. The primary polyclonal TS antibody was diluted 1:100 in 1% bovine serum albumin (BSA)/PBS and incubated for 1 hr at room temperature. Normal rabbit serum was used as a control for aspecific staining. After PBS wash steps (twice for 5 min), the secondary antibody (DAKO; Glostrup, Denmark), biotin-labeled (1:800) goat anti-rabbit, was applied and incubated for 30 min. The sections were rinsed again with PBS (twice for 5 min) and incubated with horseradish peroxidase-labeled avidin–biotin complex for 30 min, according to the recommendation of the manufacturer; 3-amino-9-ethylcarbazole (AEC) was used as a chromogen. The sections were counterstained with hematoxylin. All slides were examined by two observers in independent examination sessions. The whole sample was evaluated by scoring at least four high-power fields (x10 and x40 magnification). Statistical evaluation was performed using SPSS software.

To compare the polyclonal TS antibody with the TS monoclonal antibody TS 106 (kindly provided by Dr. P.G. Johnston; then at the National Cancer Institute, Bethesda, MD) which has already been extensively characterized, we used the same protocol as above. The monoclonal antibody was 1:50 diluted in 1% BSA/PBS and incubated for 1 hr followed by incubation with the second goat anti-mouse biotin-labeled antibody (1:50). As a negative control, a mouse IgG1 antibody was used.

Western Immunoblotting and Enzyme Assays
For further characterization of the antibody with Western immunoblotting, monolayer SW1573 cancer cells in exponential growth phase were treated for 24 hr at 50% growth-inhibitory concentrations of either 5FU or the TS inhibitors AG377 and ZD1694. Treated and control cells were harvested, washed, and centrifuged, and the pellets were immediately frozen in liquid nitrogen and processed essentially as described previously (Van Triest et al. 1997 ). Samples were kept at -80C. The cytosolic cell fraction was isolated by lysis in buffer containing 0.1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.6, 5 mM EDTA, and centrifuged for 10 min at 15,000 x g at 4C. From each sample an equivalent amount of protein (50 µg) was loaded on a 12% SDS-polyacrylamide gel, followed by blotting onto nitrocellulose PVDF membranes. Thereafter the membranes were blocked overnight with blocking buffer (1% nonfat dry milk, 1% BSA in 10 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.05% Tween-20). The primary antibody, rabbit anti-human TS (1:3000 in blocking buffer) was incubated for 1 hr. Then, the blot was incubated with the secondary antibody (1:1000 in blocking buffer), horseradish peroxidase-conjugated goat anti-rabbit antibody. Finally, the blot was stained using AEC as a chromogen. The density of the bands was quantified using a densitometer (G690; Biorad Laboratories, Nazareth, Belgium). TS enzyme levels were determined enzymatically as described previously (Peters et al. 1991 ; Van Triest et al. 1999 ).


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Immunohistochemistry
Antigen retrieval with citrate buffer, pH 6.0, was essential for positive staining of the formalin-fixed, paraffin-embedded tumor samples. Titration of the primary TS antibody concentration between 1:50 and 1:500 resulted in optimal staining when a concentration of 1:100 was used. Antigen retrieval was necessary; omission of this step resulted in nonevaluable samples. After the retrieval step, all samples could be evaluated. An example of a colon tumor stained with the TS polyclonal antibody is shown in Fig 1. Positive staining with the polyclonal TS antibody gave a granular cytosolic staining pattern in the tumor cells. In most tumor samples the staining was diffuse, although heterogeneity was also observed. The intensity of the staining was scored as low, intermediate, or high (1+ to 3+) and in Fig 1 an example is shown. Fig 1A is high intensity, Fig 1B intermediate, and Fig 1C low intensity. Normal colon epithelial cells showed weak positive staining, but this was much weaker than in tumor cells (Fig 1D). There was more intense staining at the proliferative zone. A colon tumor sample of a patient with high TS expression was always used as a positive control and gave a similar staining pattern in each separate experiment. The results of the immunostaining were as follows: 17 patients had 1+, 24 had 2+, and nine patients had a high TS level of 3+. Therefore, the majoritiy of the patients had an intermediate TS intensity. The reproducibility of this staining was tested by replicate staining of 50 samples and was 90%. The interobserver variability was tested between two observers (BvT and BML) and was acceptable, with a kappa of 0.45. On 36 of the 50 samples the two observers agreed. When the observers disagreed on the results of the TS staining, the debate was on differences between 1+ or 2+ or differences between 2+ and 3+. The slides were then re-examined by both observers and agreement was obtained. This antibody was also suitable for immunostaining on cytospins of tumor cell lines and on frozen tissue (not shown). The polyclonal and monoclonal TS antibodies showed comparable results. TS staining was identical concerning the intensity of the tumor and normal tissue in 12 different samples from paraffin-embedded tumor sections. No differences in background staining could be observed between the polyclonal and the monoclonal antibody.



View larger version (124K):
[in this window]
[in a new window]
 
Figure 1. Immunohistochemical staining of thymidylate synthase (TS) in a human colon cancer tumor. The TS polyclonal antibody was used at a concentration of 1:100. (A) Sample with high-intensity TS staining 3+; (B) sample with intermediate intensity TS staining 2+; (C) sample with low staining (1+); (D) sample with normal colon tissue with an overall low intensity staining, although a higher intensity was found at the proliferative zone. Assignment of positivity was based on the type of staining that was most abundant. Bars = 30 µm.

Western Immunoblotting and TS Activity Level
To evaluate the specificity of the antibody, TS Western blotting was performed in the human non-small-cell lung cancer cell line SW1573 (Fig 2) and in a panel of 13 human colon cancer cell lines (Van Triest et al. 1999 ). The band for TS was as expected at 36 kD. No additional bands were observed in this blot and no nonspecific products could be visualized, so the detection of the TS protein level was highly specific. After treatment with 5FU, a ternary complex is formed between TS, FdUMP, and 5,10-methylenetetrahydrofolate, which can be seen as an additional band in the second lane, indicated as T (= ternary complex) and N (= normal TS). The polyclonal and monoclonal antibodies were also compared during Western immunoblotting. For both antibodies, the band for TS could be visualized at the same MW. No other additional bands could be detected. The results indicated that on Western blots both antibodies were also comparable. In 13 colon cancer cell lines, intensity of Western blotting was compared with enzyme levels; a positive linear relationship was observed between both parameters (r=0.62; p<0.05). In a separate group of 32 patients, immunohistochemistry was compared with enzyme levels; here the relationship tended to be significant (r=0.53; p=0.07) (Van Triest et al. in press ).



View larger version (51K):
[in this window]
[in a new window]
 
Figure 2. Western blot using the TS polyclonal antibody (1:3000) on SW1573 human non-small-cell lung cancer cells. Each lane represents a sample of cells treated for 24 hr with 50% growth-inhibitory concentrations of AG337, ZD1694, or 5FU. The right lane contains a sample of untreated cells. In each lane a band is observed at 36 kD, which represents the native enzyme. An additional higher molecular weight band is found in the 5FU-treated cells, which is the ternary complex formed by FdUMP–thymidylate synthase and CH2–THF.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

In this article we describe the results of the validation of a polyclonal antibody for TS staining in paraffin-embedded colon or rectal tumor material. This polyclonal antibody was highly specific and could detect the TS protein using Western immunoblotting and immunohistochemistry. A discrimination between high and low TS levels could easily be measured in 50 samples of patients with colon tumors. In the tumor material, the method for the TS immunostaining was reproducible and showed acceptable intraobserver variability.

For immunostaining with the polyclonal TS antibody, various methods of detection have been used. For detection of TS in tumor cell lines we initially used a direct peroxidase-labeled secondary antibody (Van der Wilt et al. 1993 ). Findlay et al. 1997 used an immunogold probe with silver enhancement for paraffin-embedded material because alkaline phosphatase-labeled secondary antibodies were not sensitive enough. This technique is indirect, and an immunoglobulin absorbed to colloidal gold is used as the secondary antiserum. The gold particles attached to the specific antibody are revealed by a silver precipitation technique. Although being a very sensitive technique, the antigen recognition strongly depends on the size of the gold probe (Holgate et al. 1983 ). In our study, we used a biotin-labeled secondary antibody coupled to an avidin–biotin–peroxidase complex. A disadvantage of this ABC method may be the binding of avidin to endogenous biotin. However, the very coarse granular cytosolic staining typical for binding to endogenous biotin was not seen in our samples. For the detection of TS with the monoclonal antibody TS-106, the indirect ABC method was also used for amplification of the signal (Johnston et al. 1991 ; Edler et al. 1997 ). Studies on detection of other cytosolic proteins, such as bcl-2, by immunohistochemistry in colorectal tumors also used anti-peroxidase, anti-alkaline phosphatase (Schneider et al. 1997 ), or the ABC method (Merritt et al. 1995 ) for specific detection of the primary antibody, without evidence of a very coarse granular cytosolic staining.

A comparison with the TS monoclonal antibody developed by Johnston et al. was undertaken to determine whether these antibodies could be used interchangeably. Both antibodies showed similar results for the intensity of staining of tumor and normal tissue, the background and on TS Western immunoblotting (Johnston et al. 1992 ; Drake et al. 1993 ; Edler et al.. 1997 ) and can be used to determine TS expression by immunostaining in paraffin-embedded material such as from ECOG, NSABP, SWOG, and EORTC studies for the monoclonal antibody. The polyclonal antibody is now being used for large-scale screening of TS expression in paraffin-embedded tumor material from patients with colorectal cancer Stages B and C, entered in a randomized study, either with no further treatment or adjuvant treatment with the combination of 5FU plus levamisol. This will enable us to determine whether TS levels are of predictive value for treatment outcome of adjuvant 5FU-based therapy.

Received for publication December 29, 1999; accepted January 12, 2000.
  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Aherne GW, Hardcastle A, Newton R (1992) Measurement of human thymidylate synthase (hTS) in cell lines using ELISA. Ann Oncol 3(suppl 5):77[Medline]

Brown RW, Chirala R (1995) Utility of microwave citrate antigen retrieval in diagnostic immunohistochemistry. Mod Pathol 8:15-20

Drake J, Allegra CJ, Johnston PG (1993) Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS-106. Anti-cancer Drugs 4:431-435[Medline]

Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer—methodological studies. Eur J Cancer 33:2278-2281[Medline]

Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 75:903-909[Medline]

Freemantle SJ, Aherne GW, Hardcastle A, Lunec J, Calvert AH (1991) Increases in thymidylate synthase protein levels measured using newly developed antibodies. Proc Am Assoc Cancer Res 32:360

Holgate CS, Jackson P, Cowen PN, Bird CC (1983) Immunogold-silver staining: new method of immunostaining with enhanced sensitivity. J Histochem Cytochem 31:938-944[Abstract]

Jackman AL, Calvert AH (1995) Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871-881[Abstract]

Johnston PG, Drake JC, Trepel J, Allegra CJ (1992) Immunological quantitation of thymidylate synthase using the monclonal antibody TS-106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52:4306-4312[Abstract]

Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647[Abstract]

Johnston PG, Liang C-M, Henry S, Chabner BA, Allegra CJ (1991) Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51:6668-6676[Abstract]

Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE (1997) Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89:308-313[Abstract/Free Full Text]

Leichman L, Lenz H-J, Lechman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, Stain S, Beart R, Danenberg P (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31:1306-1310

Lenz H-J, Hill C, Danenberg KD, Leichmann LL, Priest DG, Danenberg PV (1995) Rapid quantitative PCR for determination of relative gene expressions in tissue specimens. PCR Methods Applications 4:305-308[Medline]

Lenz H-J, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182[Abstract]

Merritt AJ, Potten CS, Watson AJM, Loh DY, Nakayama K-I, Nakayama K, Hickman JA (1995) Differential expression of bcl-2 in intestinal epithelia; correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 106:2261-2271

Peters GJ, Ackland SP (1996) New antimetabolites in preclinical and clinical development. Exp Opin Invest Drugs 5:637-679

Peters GJ, Jansen G (1996) Resistance to antimetabolites. In Schilsky RL, Milano GA, Ratain MJ, eds. Principles of Antineoplastic Drug Development and Pharmacology. New York, Marcel Dekker, 543-585

Peters GJ, Laurensse E, Leyva A, Pinedo HM (1987) Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 23:1869-1881[Medline]

Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12:2035-2042[Abstract]

Peters GJ, Van Groeningen CJ, Laurensse E, Pinedo HM (1991) Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxyuridine-5'-monophosphate. Eur J Cancer 27:263-267[Medline]

Pinedo HM, Peters GJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664[Abstract]

Reynolds T (1995) Dutch trial casts doubt on colorectal adjuvant therapy. J Natl Cancer Inst 87:476-479[Medline]

Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin M-B, Wilke H, Seeber S (1997) Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15:389-400[Abstract]

Schneider HJ, Sampson SA, Cunningham D, Norman AR, Andreyev HJN, Tilsed JVT, Clarke PA (1997) Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 75:427-431[Medline]

Taylor CR, Shi S-R, Chaiwun B, Young L, Imam SA, Cote RJ (1994) Strategies for improving immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections. Hum Pathol 25:263-270[Medline]

Van der Wilt CL, Smid K, Aherne GW, Pinedo HM, Peters GJ (1993) Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. Adv Exp Med Biol 338:605-608[Medline]

Van der Wilt CL, Smid K, Noordhuis P, Aherne GW, Peters GJ (1997) Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 33:471-478[Medline]

Van Triest B, Pinedo HM, Telleman F, Van der Wilt CL, Jansen G, Peters GJ (1997) Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 53:1855-1866[Medline]

Van Triest B, Pinedo HM, Van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, Van der Wilt CL, Van Laar JAM, Noordhuis P, Jansen G, Peters GJ (1999) Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but for folate-based thymidylate synthase inhibitors in 13 non-selected colon cancer cell ines. Clin Cancer Res 5:643-654[Abstract/Free Full Text]

Van Triest B, Pinedo HM, Blauwgeers JLG, Van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HFW, Peters GJ (in press) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res